The use of dulaglutide in real clinical practice in patients with type 2 diabetes mellitus in Moscow
- Авторлар: Antsiferov M.B.1, Antsiferova D.M.1,2, Koteshkova O.M.1, Demidov N.A.3
-
Мекемелер:
- Endocrinological Dispensary of the Moscow Healthcare Department
- Russian Medical Academy of Continuous Professional Education
- City Hospital of Moscow City of the Moscow Healthcare Department
- Шығарылым: Том 31, № 2 (2024)
- Беттер: 77-84
- Бөлім: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/632402
- DOI: https://doi.org/10.18565/pharmateca.2024.2.77-84
- ID: 632402
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Objective. Evaluation of the effectiveness of dulaglutide in real clinical practice for patients with type 2 diabetes mellitus (DM2) in Moscow.
Methods. To assess the main indicators of DM2 patients using dulaglutide in therapy, a sample was formed from the Moscow segment of the Federal Register of Diabetes Mellitus (FRDM) as of 02/14/2024. To assess the effectiveness of dulaglutide therapy over a 5-year follow-up period, an additional sample of patients from the Moscow segment of the FRDM who began treatment with dulaglutide in 2018 was formed.
Results. When assessing the dynamics of carbohydrate metabolism control indicators over a more than 5-year follow-up period (2018–02/01/2024), a trend towards a decrease in HbA1c levels from 7.3 to 7.0% was noted (p>0.05). In the subgroup of patients who did not receive insulin therapy, a statistically significant decrease in HbA1c levels from 7.3 to 6.7% was demonstrated (p=0.04); there was no statistically significant change in HbA1c levels on insulin therapy (7.5±1.1 versus 7.7±1.1%; p>0.05). When assessing the dynamics, a statistically significant decrease in body weight from 102.9±21.8 to 98.4±19.6 kg, a decrease in body mass index (BMI) from 35.6 to 33.5 kg/m2 (p<0.05) primarily in patients who did not receive insulin therapy (p<0.05) was noted. In patients on insulin therapy, there were no statistically significant differences in the dynamics of body weight and BMI.
Conclusion. The use of dulaglutide in real clinical practice demonstrates long-term maintenance of glycemic control indicators within or close to target values and a statistically significant reduction in body weight and BMI. The greatest effectiveness in achieving glycemic control, reducing body weight and BMI was achieved in a cohort of DM2 patients not receiving insulin medications.
Негізгі сөздер
Толық мәтін
Авторлар туралы
M. Antsiferov
Endocrinological Dispensary of the Moscow Healthcare Department
Email: koala58@mail.ru
ORCID iD: 0000-0002-9944-2997
SPIN-код: 1035-4773
Ресей, Moscow
D. Antsiferova
Endocrinological Dispensary of the Moscow Healthcare Department; Russian Medical Academy of Continuous Professional Education
Email: koala58@mail.ru
ORCID iD: 0000-0002-3920-5914
Ресей, Moscow; Moscow
O. Koteshkova
Endocrinological Dispensary of the Moscow Healthcare Department
Хат алмасуға жауапты Автор.
Email: koala58@mail.ru
ORCID iD: 0000-0001-8428-4116
SPIN-код: 6141-1224
Cand. Sci. (Med.), Head of the Department of Education and Treatment of Diabetes
Ресей, MoscowN. Demidov
City Hospital of Moscow City of the Moscow Healthcare Department
Email: koala58@mail.ru
ORCID iD: 0000-0001-8289-0032
SPIN-код: 7715-4508
Ресей, Moscow
Әдебиет тізімі
- www. diabetesatlas.org. Facts & figures (idf.org) URL: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
- Анциферов М.Б., Демидов Н.А., Калашникова М.Ф. и др. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом, проживающих в Москве (2013–2018). Сахарный диабет. 2020;23(2):113–24. [Antsiferov M.B., Demidov N.A., Kalashnikova M.F. and others. Dynamics of the main epidemiological indicators in patients with diabetes mellitus living in Moscow (2013–2018). Diabetes mellitus. 2020;23(2):113–24. (In Russ.)]. doi: 10.14341/DM11374.
- American Diabetes Association. Diab Care. 2023;46(Suppl. 1):S1–298.
- Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы диагностики и лечения сахарного диабета. Сахарный диабет. 2023;26(Suppl. 2):1–231. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. Algorithms for the diagnosis and treatment of diabetes mellitus. Diabetes mellitus. 2023;26(Suppl. 2):1–231. (In Russ.)]. doi: 10.14341/DM13042.
- Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.
- Shyangdan D.S., Royle P., Clar C., et al. Glucagon-like peptide analogues for type 2 diabetes malloitus. Cochrane Database Syst. Rev. 2011;2011:CD006423. doi: 10.1002/14651858.CD006423.pub2.
- Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diab Obes Metab. 2016;18(3):203–16. doi: 10.1111/dom.12591.
- Frias J.P., Bonora E., Nevarez Ruiz L., et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diab Care. 2021;44:765–73. Doi: 10.2337/ dc20-1473.
- Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. doi: 10.1016/S0140-6736(19)31149-3.
- Botros F.T., Gerstein H.C., Malik R., et al. Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diab Care. 2023;46(8):1524–30. doi: 10.2337/dc23-0231.
Қосымша файлдар
